DB05142ExperimentalSmall molecule
ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic... It is a new type of antidepressant drug with anxiolytic activity.
- Primary indication
- Investigated for use/treatment in anxiety disorders and depression.Curator reviewed
- Code names
- ND7001
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with ND7001, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account